Eisai has been granted a patent for a method to treat tumors expressing Neuropilin 1 by administering a chlorotoxin agent. The agent includes a polypeptide with specific characteristics and binding capabilities. This innovation offers potential advancements in cancer detection and treatment. GlobalData’s report on Eisai gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Eisai Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Eisai, Human telomerase RT biomarker was a key innovation area identified from patents. Eisai's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Method for treating tumor expressing neuropilin 1 with chlorotoxin agent

Source: United States Patent and Trademark Office (USPTO). Credit: Eisai Co Ltd

A recently granted patent (Publication Number: US11826399B2) discloses a method for treating tumors expressing Neuropilin 1. The method involves determining the expression of Neuropilin 1 in a tumor sample from a subject and administering a chlorotoxin agent to the subject if the tumor is found to express Neuropilin 1. The chlorotoxin agent contains a specific polypeptide sequence that binds to Neuropilin 1, with the option to include a therapeutic payload such as anti-cancer agents like BCNU, cisplatin, or paclitaxel.

Furthermore, the patent claims cover the use of chlorotoxin agents associated with targeting moieties, imaging moieties, or detectable moieties for various applications. These applications include imaging tissues, diagnosing cancer, detecting cancerous tissues for removal, and identifying tumors during surgery. The chlorotoxin polypeptide's ability to bind Neuropilin 1 is confirmed through in vitro binding assays, ensuring its efficacy in targeting tumors expressing Neuropilin 1. Additionally, the method allows for the administration of chemotherapeutic agents in conjunction with the chlorotoxin agent for enhanced treatment outcomes.

To know more about GlobalData’s detailed insights on Eisai, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies